Viking Therapeutics (NASDAQ: VKTX) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may ...

DelveInsight recently conducted an in-depth MASH Market Size and Share Assessment to help a pharmaceutical client understand the ...

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

And Novo Nordisk (NYSE: NVO) stock, down 4.9%, is the victim. Where to invest $1,000 right now? Our analyst team just ...

Bullish option flow detected in Viking Therapeutics (VKTX) with 8,905 calls trading, 2x expected, and implied vol increasing over 15 points to ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report). The ...

CordenPharma and Viking Therapeutics sign multi-year strategic partnership to support the commercial demand of Viking Therapeutics' GLP-1 drug candidate VK2735.CordenPharma provides large-scale ...

Boehringer Ingelheim and Veeva Systems have announced the launch of Boehringer's One Medicine Platform, powered by the successful implementation of Veeva Development Cloud. They first announced the ...

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

In this article, we are going to take a look at where Viking Therapeutics, Inc. (NASDAQ:VKTX) stands against the other stocks. The stock market fell further into negative territory on Tuesday as ...

Viking Therapeutics, Inc. has a 1 year low of $24.41 and a 1 year high of $96.74. The stock has a market cap of $3.15 billion, a PE ratio of -28.09 and a beta of 0.90.

A live webcast of the Leerink presentation may be accessed via a link on the Viking Therapeutics website in the Investors & Media section under Webcasts. Additionally, a replay of the webcast will ...